ProBioGen AG and Immunogenesis, Inc., a spin-off of the MD Anderson Cancer Center, have signed a Service Agreement for the cell line development, process development and GMP manufacture of Immunogenesis’ lead immuno-oncology candidate in 1,000 L bioreactor scale.

Immunogenesis’ first-in-class monoclonal antibody candidate has two different specificities resulting from R&D work at the MD Anderson Cancer Center, University of Texas. Using its CHO.RiGHT expression platform for high-titer cell line development, ProBioGen will support the development and conduct large-scale manufacturing in ProBioGen’s new facility. Now, with 2 facilities in Berlin, ProBioGen is prepared to accommodate the increased demand for manufacturing.

“We are very excited to enter the development and manufacturing phase with our lead candidate”, said Michael A. Curran, founder of Immunogenesis and associate professor at the MD Anderson Cancer Center. “And with ProBioGen we found the right partner that has great scientific expertise and the ‘can-do’ mindset which we very much appreciate for this challenging step.”

Dr. Wieland Wolf, CEO of ProBioGen, “It is great to be part of the transition of the molecule to the clinic, and we are looking forward working together with Immunogenesis on the realization of their project.”